Physical exam • HR - 90/min RR - 20/min BP - 130/70 • Lung - ↓ Rt. base • Abdonminal distension / Clinical ascites • Abdominal / Pelvic mass
Case report
Ovarian cancer
Ami Fishman, M.D.
Meir Hospital - Sapir Med Center
Kfar-Saba, Israel
10.2001
57y-o, G3P2,
upper abdominal pain ⊕ discomfort - 3mo, abdominal girth increase ~ 1mo
◊
???
57y-o, G3P2,
upper abdominal pain + discomfort - 3mo, abdominal girth increase ~ 1mo
↓
H
History
• General
• Gynecologic - Reproductive
• Familial
Physical exam
• HR - 90/min RR - 20/min BP - 130/70
• Lung - ↓ Rt. base
• Abdonminal distension / Clinical ascites
• Abdominal / Pelvic mass
work-up
↓
???
work-up
↓
Blood:
- CBC + SMA + Coag. profile
- Tu markers
- Genetics / molecular
work-up
↓
Imaging:
-Chest X-ray
- Abdominal CT
- U/S
- GITr/GUTr
- Mammography
Chemotherapy
Neo-adjuvant chemotherapy
- Taxol + Carboplatin
- No. of cycles?
- Interval debulking
- Response parameters
Ovarian Ca - advanced disease Treatment
Standard of care:
↓
Primary surgical cytoreduction followed by platinum-based chemotherapy
Ami Fishman, M.D.
Surgery
• Objective - advanced disease - early disease
Pre-op work-up
- Routine blood + Cross & Type
- Prophylactic heparin
- Anesthesia clearance
- G.I.Tr. Prep
• mechanical
• antibiotics
Surgery
Debulking
- rational
- definitions
- procedures
Ovarian Ca - advanced disease
Optimal Residual Disease
better prognosis
no residual tumor
< 0.5 cm
0.5-1.5 cm
Ami Fishman, M.D.
Surgery
• Objective - early disease
• Staging - rational
- procedures
Ovarian Ca - advanced disease Treatment
~ 40 - 60%
Rate of achieving optimal primary cytoreductive surgery
Ami Fishman, M.D.
Adjuvant chemotherapy
• Definitions
• Protocol
• Combinations
Adjuvant chemotherapy
• Taxol + Carboplatin
• Side effects
- Systems
- Limiting
• Routine F/U
Adjuvant chemotherapy
• Carboplatin (Calvert AUC= 6-7)
• Taxol (175 mg/m2)
• x6 courses q3 weeks
Ami Fishman M.D.
Adjuvant chemotherapy
Platinum + Taxol
• Response Rate (clinical) = 70-80%
• end of RX - ???
• Platinum sensitive
• Platinum resistant
Ami Fishman M.D.
Chemotherapy
• Response definitions:
- Complete
- Partial
- Stable disease
- Progression
15 mo following last chemotherapy cycle
Asymptomatic
CA-125 = 10/2000 => 17
01/2001=> 67
◊
???
Elevated CA-125
• Asymptomatic patient
- Evaluate disease
To treat or not to treat??
2nd line chemotherapy
• Chemo-sensitive
• Chemo-resistant
2nd line chemotherapy
• Re-induction
• Others - old agents
- new agents
• High dose
• Intra-peritoneal
• Research protocols
Research protocol
• Phase I/II/III
• protocol end points
37 y-o
7cm ovarian complex cyst
↓
• Larparoscopy
↓
Procedures:
• peritoneal washing for cytology
• Frozen section
Frozen section
==> LMPT
↓
• ???
Procedures:
• USO
• Surgical staging:
omentectomy + peritoneal biopsies
+ retrop. LN sampling
37 y-o, Laparosscopic USO
Final histology (after 10 days) ==>
Ovarian Ca
↓
???
Review/confirm histology
Consider:
- grade
- age & reproductive plan
- site /experience of surgeon at 1st procedure
- referral to Gyn-Onc
Shift towards neoadjuvant chemotherapy found in ovarian cancer treatment
October 21st 2024A recent study shows a significant decrease in primary cytoreductive surgery utilization for advanced ovarian cancer, as neoadjuvant chemotherapy followed by interval cytoreductive surgery gains acceptance for its noninferior survival outcomes and reduced postoperative morbidity.
Read More
Family history criteria used to predict breast cancer genetic risk variants
September 26th 2024In a recent study, patients with a positive response to the Seven-Question Family History Questionnaire were more likely to present with a pathogenic or likely pathogenic variant in the BRCA1 and BRCA2 genes.
Read More
Offering cervical and colorectal cancer screening at breast cancer screening found effective
August 26th 2024In a recent study, women overdue for cervical cancer and colorectal cancer screening were more likely to receive coverage when offered during their breast cancer screening visit.
Read More